about
The visual pathway as a model to understand brain damage in multiple sclerosis.Lesions in the posterior visual pathway promote trans-synaptic degeneration of retinal ganglion cellsTrans-synaptic axonal degeneration in the visual pathway in multiple sclerosis.Oxaliplatin-Related Ocular ToxicityRandomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis.The multiple sclerosis visual pathway cohort: understanding neurodegeneration in MS.Usefulness of optical coherence tomography to distinguish optic neuritis associated with AQP4 or MOG in neuromyelitis optica spectrum disorders.Optical coherence tomography findings in spinocerebellar ataxia-3.Ocular syphilis--back again: understanding recent increases in the incidence of ocular syphilitic disease.Treatment of acute optic neuritis and vision complaints in multiple sclerosis.Changes in macular layers in the early course of non-arteritic ischaemic optic neuropathy.Pathological findings in the lens capsules and intraocular lens in chronic pseudophakic endophthalmitis: an electron microscopy study.Early retinal atrophy predicts long-term visual impairment after acute optic neuritis.Retinal infarcts in a patient with an acute confusional syndrome.Is the incidence of optic neuritis rising? Evidence from an epidemiological study in Barcelona (Spain), 2008-2012.Phenytoin for neuroprotection.[Papilledema as an indicator of POEMS syndrome].Dynamic molecular monitoring of retina inflammation by in vivo Raman spectroscopy coupled with multivariate analysis.Ocular tilt reaction as a delayed complication of deep brain stimulation for Parkinson disease.Visual field impairment captures disease burden in multiple sclerosis.Retrobulbar versus peribulbar block: alfentanil in eye blocks.Color vision impairment in multiple sclerosis points to retinal ganglion cell damage.Predictors of vision impairment in Multiple Sclerosis.Neuro-Ophthalmological Features of Primary Diffuse Leptomeningeal GliomatosisSíndrome del ocho y medio[Neuro-ophthalmological manifestations of pituitary adenomas. The usefulness of optical coherence tomography]Dynamics of retinal injury after acute optic neuritis[Retinopathy caused by desferrioxamine][Current indications of botulinum toxin treatment]Young boy with progressive double vision[Sinus syndrome, an uncommon cause of enophthalmos]Not just for menTwo cases of drug-induced orbital inflammatory diseaseMultidisciplinary management of multiple sclerosis symptomsColour vision impairment is associated with disease severity in multiple sclerosis[Comparison of three optical coherence tomography devices, one time-domain and two fourier-domain, for the estimation of the retinal nerve fibre layer thickness]Nystagmus: an uncommon neurological manifestation of thiamine deficiency as a serious complication of sleeve gastrectomyRetinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT studyUsing Acute Optic Neuritis Trials to Assess Neuroprotective and Remyelinating Therapies in Multiple Sclerosis[Integration of primary care ophthalmology in the hospital: Comparative analysis of results]
P50
Q30836017-39519EA0-56C7-4095-948D-F340B81699A0Q33654849-2E7E86B1-199F-488B-AE56-520ADAAC2AFCQ34376913-A86CAB5D-30E8-42C6-8424-ED3F3C7ECB2FQ34394155-23DD8739-74E2-4F47-8BEA-98E5E7A7377BQ34600820-1004338F-01D9-499C-ACED-6CE637C04FCEQ34991161-F3395C42-E04C-4C6F-B372-D8F6A09C5954Q37197191-335424AB-AF32-4A8B-A308-6831496ACFC4Q37406826-497E3B1A-A8C4-423C-8765-8C7167585A25Q37544519-636A74AB-9E6A-4956-AA27-776D5858B697Q38268540-6CE80F8E-D8D1-4157-BEA4-6F41EDFA5A8FQ38504485-2E012570-570C-4EED-B7AA-F6D41C087B2CQ45009134-273DB275-5583-4A34-A263-E7B4AC7423A3Q45151446-6AC8C343-4272-4521-85B9-F0D79607368BQ45962168-131F176A-6D6B-46DB-A05E-CBF83DADBAC3Q45970017-E9A194C8-1ADD-4E10-8F5D-2774E98104F3Q45992590-FB8A0CEC-5E03-4AE0-A59C-863C05FFC3A5Q46196617-2B848DB9-1117-4EFB-B826-701CBB3D80DAQ46468264-6E46081A-2982-4DB5-AE1F-D2308A9F4911Q48393037-C3309AD2-48A9-4F8A-B187-1FEBBFF41EE0Q48919888-2342AF24-A04D-4E4D-8A53-05B1ADC06206Q51576115-5F6F890C-987D-4E3B-9B2C-ABC3C16C39D0Q53384776-E08234AA-BD3C-4342-9070-FF0CB21F679FQ55010300-FA590CEF-FF7D-477E-9584-E667B22047B1Q57767953-2F24F6EB-9E1B-4AA7-AC5C-421CCF508D7CQ57767987-6CD249FC-F42C-40FF-82E1-B309E73C6089Q57767993-11E5BBC4-F4F7-4730-BCB2-B01B1438A8BCQ60461877-5E0F2BE9-DA09-44A4-B82D-2BEC9F42F7CDQ73141405-DBB373B8-B184-41AC-8A5C-75AB1BDC4E43Q73332183-0B826283-A47B-46E9-9893-7B3E1956FE6EQ77144030-0BDA44DB-2D01-4631-90E0-E6969C26D466Q80660308-2CD3A0B8-46B6-4DF0-9299-0E636AD7BB0EQ82236527-E8B4E118-093C-443D-98C4-8DA024CE5351Q83330245-D3F84B12-9CEC-424D-BD40-00446AFFB4C7Q85670296-6BE99B19-363A-43C9-8F47-E4C5DE87947BQ87051521-9C481775-9CE5-46FA-97D1-53D7AE215A3DQ87375838-C9D97EEF-6146-4202-BDEA-B6D292B50CBFQ87415976-6387C60A-AF06-400D-9405-1EB4571AB52FQ90116408-7D6EEECC-EB89-4C8D-80C0-2F0BE26F9E1DQ90365092-08380E9D-F86F-4AD9-9ED3-25C9760957DDQ91494986-9106A007-3883-44B0-8467-989DBA3B30A4
P50
description
researcher
@en
name
Bernardo F. Sanchez-Dalmau
@en
Sanchez-Dalmau B
@nl
type
label
Bernardo F. Sanchez-Dalmau
@en
Sanchez-Dalmau B
@nl
altLabel
Sanchez-Dalmau B
@en
prefLabel
Bernardo F. Sanchez-Dalmau
@en
Sanchez-Dalmau B
@nl
P106
P31
P496
0000-0001-8950-9759